Viking Therapeutics' stock soars 61% premarket after company reports positive results in trial of weight-loss drug

Viking posted positive results from a mid-stage trial of its GLP-1 drug.

Related Keywords

,Drug Administration ,Therapeutics Inc ,Viking Therapeutics ,Article Normal ,Biotechnology ,Pharmaceuticals ,Machinery ,Agricultural Machinery ,Health Care ,Biopharmaceuticals ,Specialized Drugs Medications ,Hormone Products ,Industrial Goods ,Diabetes Drugs ,Regulation Government Policy ,Financial Performance ,Share Price Movement Disruptions ,New Products Services ,Research Development ,Corporate Industrial News ,Products Services ,New Product Service Testing ,Political General News ,Society Community ,Diabetes ,Physical Mental Fitness ,Health ,Living Lifestyle ,Medical Conditions ,Obesity ,Social Issues ,Weight Management ,Content Types ,Factiva Filters ,C Amp Ampe Exclusion Filter ,C Amp Ampe Industry News Filter ,Viking Therapeutics Inc ,Vktx ,Novo Nordiskas Adr ,Nvo ,Novo Nordiska S ,Dk Novo B ,Eli Lilly Amp Co ,Rally ,Spx ,S Amp Ampp 500 Index ,Regulation ,Government Policy ,Share Price Movement ,Disruptions ,New Products ,Services ,Research ,Development ,Corporate ,Industrial News ,Products ,New Product ,Service Testing ,Political ,General News ,Society ,Community ,Physical ,Mental Fitness ,Living ,Lifestyle ,Specialized Drugs ,Medications ,